Patent lawyers in the field of biotechnology don't get bored. The science they review is constantly changing and so are the laws governing how new scientific discoveries should be evaluated. This is particularly true when it comes to stem cells-a new field with a lot of commercial potential. "The situation is similar to the plant transformation field in the 1980s and 1990s," says Erich E. Veitenheimer, a partner in the Washington DC office of Cooley Godward Kronish LLP, a law firm that specializes in biotechnology patent claims. "There is a lot of activity. Lots of people finding similar things, so there are a lot of interferences, re-examinations, oppositions, litigations, and eventually cross-licensing."
A good example is the highly publicized challenge to three foundational patents on primate (including human) embryonic stem cells granted by the US Patent and Trademark Office (USPTO) to the Wisconsin Alumni Research Foundation (WARF) in 1998 and 2001. The patents were challenged by two consumer groups-the New York-based Public Patent Foundation and the California-based Foundation for Taxpayer and Consumer Rights-who argued that the methods for isolating a primate stem cell line were obvious based on previous work ("prior art") and therefore were not patentable. The concern expressed by the two groups was that the broad claims in the three patents were hindering human embryonic stem cell research in the US by requiring researchers to negotiate a costly license with WARF in order to work in this area. In October 2006, the USPTO agreed to re-examine the three WARF patents, although it could take years for the re-examination process to be concluded; for the time being the patents continue to be valid.
The European WARF Case
In Europe, the patenting of human embryonic stem cells has been caught up in a battle not over sweeping claims but over morality. "The main issues in the US are the breadth of the patents and how they are being licensed. The main issue in Europe right now is morality," says Philip Webber, a biotech patent attorney with Frank B. Dehn & Co. in London. WARF applied to the European Patent Office (EPO) for a European patent for cell cultures comprising primate embryonic stem cells. In 2004, the EPO refused the application on moral grounds-because the invention unavoidably involves the use of human embryos. WARF appealed this decision, which is now under review by the Enlarged Board of Appeal, the highest level for resolving such disputes within the EPO.
"The European Patent Office has to decide whether human stem cellbased inventions are immoral or not," says Webber. "The decision will include philosophical and moral questions. But the EPO is a patent-granting body, not an adjudicator on what is moral or not. It is difficult to see how it will come to a conclusion." Morality does not typically come up in patent debates. "The morality issue is not as prevalent in arguments over other biotech inventions," says Sarah Turner, a solicitor at the London office of the international law firm Lovells LLP. "With inventions like antibodies you tend to argue based on more standard arguments against patentability, for example that the invention was obvious," says Turner.
But debates over morality are not entirely new to biotech patent law in Europe. The most notable case was Harvard University's "oncomouse"-a transgenic mouse highly susceptible to cancer, created in the early 1980s by Philip Leder and Timothy Stewart. The patent application was filed in 1985 with the EPO, which considered the case at length, at many levels, and amidst much debate. The EPO eventually granted the patent in 1992-a decision that was opposed by animal-rights groups, church organizations, and various sections of the German Green party, who felt that the suffering caused to the animals was immoral. But in the end, the patent was maintained because the EPO held that the application's purpose was of such importance for humanity-to find a cure for cancer-as to outweigh the suffering of the animals concerned. And while transgenic mice raised ethical concerns, the debate has never been as heated as with human embryonic stem cells. "They are such an emotive subject," says Turner.
Ongoing Controversy
The EPO has received over 160 amicus curiae briefs regarding its impending decision on the WARF appeal from third parties who have an opinion on the fate of the application, including lawyers and biotech industry representatives, as well as religious, ethical, and green groups. The briefs show that public opinion is split and issues pertaining to stem cells are not easily settled. "The law says you cannot patent uses of human embryos for industrial or commercial purposes. You could read the wording literally. But if you have a product and had to use human embryos to get it, then it is not clear where that falls within the law," says Helen Brearley, a patent attorney with Elkington and Fife LLP in Kent, UK, adding that a decision by the EPO that "broadly" excludes patenting embryos could stifle research and innovation.
European Stem Cell Patents: Taking the Moral High Road?
A European law that prevents the patenting of discoveries that contravene morality is causing confusion when it comes to human embryonic stem cells. The ensuing debate is markedly different from the one in the United States, where the scope of stem cell patents and their licensing are under challenge. Because of existing regulations, Brearley argues that there is no need for another layer of regulation by the EPO. "The Patent Office should not decide on morality when the issue is not a clear cut decision, because in the end a patent does not give you the right to practice the invention. Instead, it just prevents others from using it," she explains. "When public opinion is divided, as in the case of stem cells, patent exclusions should be construed narrowly to exclude little rather than a lot."
What Is the Law? Rules pertaining to the patentability of human embryonic stem cells (see Table  1 Although the EPO is independent of the EU, it voluntarily adopted the Directive's rules in 1999. In contrast, member states of the EU had no choice but to implement the EU Directive directly into their country's laws. Ironically, the Directive was meant to harmonize patent law in Europe and thus stimulate the competitiveness of the biotech industry. "But it has created considerable uncertainly and disruption to patent law," says Aurora Plomer, a professor of law at the University of Sheffield, UK. Part of the problem is that the Directive was passed four months before researcher James Thomson at the University of Wisconsin, Madison reported the isolation of human embryonic stem cells in 1998. "Whether the Directive would embrace that invention was not at the forefront of discussions. So it was not debated or considered," explains Plomer. "The question arose after Thomson's article came out." This is why lawyers are now anxiously awaiting a decision on the WARF case by the EPO's Enlarged Board of Appeal so that they can have guidance. But the decision will not bring complete clarity, says WARF's intellectual property manager Paulanne Chelf. "If the EPO decides to broadly interpret [the moral exclusion], it may decide that human embryonic stem cells cannot be patented. However, if you take those cells, culture them with a cocktail of growth factors and cytokines and end up with a culture of a particular differentiated cell type, is that method patentable? You may not be destroying an embryo to do this, but using cells from an embryo that someone else destroyed," she says. "And will cells which are 'reprogrammed' from adult cells be patentable? They do not come from an embryo."
The UK Goes Its Own Way Another caveat is that not all EU member states have interpreted the Directive in the same way. "We have obtained allowance of applications in Great Britain and Sweden to claims which may be rejected ultimately in the EPO," says Chelf. The UK Intellectual Property Office (UKIPO) will not grant patents relating to processes of obtaining stem cells from human embryos or for human totipotent stem cells, which have the potential to develop into an entire human body. But, in contrast to the EPO, it will grant patents relating to human embryonic pluripotent stem cells because they do not have the potential to develop into an entire human body.
"Based on the same Directive, the UKIPO has interpreted the rules differently. It was up to the member states how they were going to interpret them," says Webber. "The UK has interpreted the Directive narrowly." This difference in approach has had some immediate effects. "We have been advising clients who want to file in Europe to file parallel patent applications with the EPO and with the UKIPO," says Webber. "They have more of a chance of getting something granted." Different laws regarding patents and research among EU member states could lead to a fragmented and confusing situation. "The legal reality is that there is diversity of regimes in Europe," says Plomer. "We could potentially end up in a situation where research laws are permissive in some countries and the moral exclusion applied to patents has the effect of not allowing that research to be patented. This was not the intention of the EU legislators when the Directive was adopted."
And while many worry that unduly restrictive patents will hinder innovation, the long-term effect is not clear cut. "The breadth of patents in the US has caused a great deal of discussion and concern about the restrictive effects of granting patents as deterring innovation and blocking further research," says Jane Gunnison, a partner in the patent practice at the firm Ropes & Gray LLP in New York City. "On the other hand in Europe, if it turns out that you cannot get a patent for human embryonic stem cells, will lack of a patent hold back innovation and research because industry wants some measure of protection for their investments? The two arguments make you aware of the complexity of the situation."
From another perspective, a lack of human embryonic stem cell patents in Europe, if that turns out to be the case, could spur researchers and companies to conduct their work in Europe, where they would be able to work in areas that could infringe a patent in the US. (They might, however, be prohibited from bringing the product of such research back to the US, depending on the nature of the product.) "People mistakenly believe that the patent system can be used to regulate activity that is of concern to the public. But that is not usually the case," says Gunnison. "There isn't that kind of direct relationship between what is patented and what people work on. If one wants to regulate activity in a technology, other kinds of legal and regulatory systems are better suited than the patent system to accomplish that."
No End in Sight?
Although a definite date has not been set, most lawyers who talked to Cell expected a decision from the EPO's Enlarged Board of Appeal regarding the WARF patent application within the year. What will the decision accomplish? "The decision may help clarify some of the confusion, but not all," says Paulanne Chelf of WARF.
As the Enlarged Board of Appeal ponders the decision, scientists are finding new sources of material for producing human embryonic stem cells. In 2007, Shinya Yamanaka of Kyoto University and James Thomson's group independently reported a method to generate human embryonic stem cell-like cells by reprogramming adult human skin cells with a cocktail of transcription factors, without the need of a human egg or embryo. "Are the Yamanaka cells caught in the morality exclusion clause? It depends on how wide the EPO will want to go with the exclusions and how much the EPO will look at the history of an invention," says Plomer. "If the application relates to a process that includes the reprogramming of a cell into an embryonic cell and if the process goes through an embryo-like state, it could be subject to the same moral exclusion [as in the WARF case]."
Experts hope that the decision by the EPO will bring some harmony within Europe by providing a European-wide standard for ethical issues in an area in which the science is quickly developing. "If the EPO seeks to impose an inappropriately broad ban on human embryonic stem cell patents in Europe, applicants may still be able to secure patent protection in selected member states," says Plomer. "The serious problem ahead lies in the lack of integration of the EPO system within EU law."
